Galcanezumab
未知生产厂商
Galcanezumab is a calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches.
Galcanezumab is a calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches.
Galcanezumab is a humanized monoclonal antibody that targets and binds calcitonin gene-related peptide (CGRP). Studies since 1985 have demonstrated that CGRP levels increase during acute migraine attacks in migraine-suffering patients but normalize after efficacious sumatriptan therapy. Also, research has shown that intravenous administration of CGRP can induce migraine-like attacks in migraine-suffering patients. For these reasons, binding to CGRP to interfere with its activity was specifically designed as the mechanism of action for galcanezumab, in order to reverse the migraine-inducing activity of natural CGRP. By binding to natural endogenous CGRP, galcanezumab interferes with its activities by making it unable to bind to CGRP receptors. Moreover, studies have shown that humanized monoclonal antibodies against CGRP have successfully reduced the frequency of migraine headaches in early clinical trials as a preventative therapeutic.
Galcanezumab is indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
共 2 项相关疾病
